FDA Approves Daraxonrasib (Rasonque): A Breakthrough Treatment for Pancreatic Cancer

A New Era for One of the Deadliest Cancers

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib (brand name Rasonque) — a first-in-class targeted therapy for metastatic pancreatic cancer that nearly doubled overall survival in clinical trials. Developed by Revolution Medicines, the daily pill is the first approved treatment that directly shuts down the mutated KRAS gene driving most pancreatic tumors, offering a critical new option for patients facing one of the most difficult-to-treat cancers in medicine.

What Is Daraxonrasib (Rasonque)?

Daraxonrasib is an oral medication known as a RAS inhibitor. It works by locking onto and switching off the mutated KRAS protein — a molecular “on switch” that sits inside more than 90% of pancreatic tumors and spurs uncontrolled cancer growth. By blocking that signal, the drug helps stop cancer cells from multiplying and spreading.

The FDA granted the drug Breakthrough Therapy designation in 2025, a status reserved for treatments of serious conditions that show early promise. The agency then approved it six months ahead of its regulatory deadline, citing “unprecedented results in an area of high unmet need,” according to Dr. Angelo de Claro, director of the FDA’s Oncology Center of Excellence.

Trial Results: Nearly Double the Survival Time

The approval is based on the RASolute 302 trial, a late-stage study of about 500 patients with previously treated metastatic pancreatic adenocarcinoma. The results were striking:

• Median overall survival: 13.2 months with daraxonrasib, versus 6.7 months with chemotherapy
• About 60% lower risk of death compared with chemotherapy (hazard ratio 0.40)
• Benefits seen in patients whose cancer had already progressed after prior systemic therapy

In other words, patients taking the pill survived, on average, nearly twice as long as those receiving standard chemotherapy.

Why Pancreatic Cancer Is So Hard to Treat

Pancreatic cancer is widely considered the deadliest of all major cancers. According to the American Cancer Society, roughly 67,000 people in the United States are diagnosed with it each year. The disease is frequently found late — after it has already spread — and more than half of patients die within three months of diagnosis.

Its biology is a major reason. KRAS mutations drive the vast majority of pancreatic tumors, and for decades researchers considered the KRAS protein “undruggable” because its surface offered no obvious pocket for a drug to grab onto. Daraxonrasib, part of a new generation of RAS(ON) inhibitors that bind the protein in its active state, finally cracks that wall.

Who Is Eligible for Daraxonrasib?

The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma (the most common form of pancreatic cancer) who:

• Have received at least one prior systemic therapy (such as chemotherapy), or
• Are not candidates for multiagent systemic therapy

It is a once-daily oral pill, which means patients can take it at home rather than traveling for infusion-based treatment.

What Are the Side Effects?

As with any cancer therapy, side effects occur. The most common ones reported in the trial were:

• Rash
• Diarrhea
• Nausea
• Fatigue
• Vomiting

Notably, about 44% of patients taking daraxonrasib experienced severe side effects, compared with 57.5% of those on chemotherapy — meaning the drug was not only more effective in the trial, but also better tolerated.

Real-World Hope: Senator Ben Sasse’s Story

The excitement around the drug is not just academic. Former U.S. Senator Ben Sasse, who announced in December 2025 that he had been diagnosed with Stage 4 pancreatic cancer, is enrolled in a clinical trial for daraxonrasib and has said the treatment has helped shrink his tumors — a powerful reminder of what these trial results mean for real patients.

What This Means for Patients and Research

The approval marks the first time a targeted RAS therapy has been approved for metastatic pancreatic cancer, and experts describe it as a paradigm shift. It validates a whole class of drugs — RAS(ON) inhibitors — that are now being tested across other KRAS-driven cancers, including lung and colorectal cancers.

For patients and families affected by pancreatic cancer, the message is hopeful: a hard-to-treat disease that once offered few options beyond chemotherapy now has a precision medicine that meaningfully extends life.

As always, patients should discuss treatment options — including eligibility for daraxonrasib — with their oncology team.

Frequently Asked Questions

What is daraxonrasib used for?

Daraxonrasib (Rasonque) is approved for adults with metastatic pancreatic adenocarcinoma who have already received at least one prior systemic therapy, or who are not candidates for multiagent chemotherapy.

How does daraxonrasib work?

It is a RAS inhibitor that binds to the mutated KRAS protein — found in over 90% of pancreatic tumors — and shuts it off, blocking the signal that drives cancer cell growth and spread.

How much longer do patients live on daraxonrasib?

In the RASolute 302 trial, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy — nearly double — with about a 60% lower risk of death.

Is daraxonrasib a pill or an infusion?

It is a once-daily oral pill taken at home.

What are the common side effects?

The most common side effects are rash, diarrhea, nausea, fatigue, and vomiting. Severe side effects were less common with daraxonrasib (44%) than with chemotherapy (57.5%) in the trial.

When was daraxonrasib approved?

The FDA approved daraxonrasib on August 26, 2026, six months ahead of its regulatory deadline.

Sources

• U.S. Food and Drug Administration — FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
• BBC News — FDA Approves Breakthrough Drug Daraxonrasib to Treat Pancreatic Cancer
• Pancreatic Cancer Action Network (PanCAN) — FDA Approves RASONQUE (daraxonrasib)
• Memorial Sloan Kettering Cancer Center — What Patients Need To Know